ArticleAmerican journal of translational research2022
Therapeutic effect of Biyuan tongqiao granules combined with mometasone furoate nasal spray on clinical symptoms of children with allergic rhinitis.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Lu'e Biyan Formula for Treatment of Allergic Rhinitis Patients with Fei (Lung)-Qi Deficiency-Coldness Syndrome: A Randomized, Double Blind, and Placebo-Controlled Trial.Chinese journal of integrative medicine · 2025Trial
- Clinical study of the effect of mometasone furoate nasal spray treatment on hearing and in secretory otitis media in children.Clinics (Sao Paulo, Brazil) · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical benefits of Biyuan Tongqiao granules (BTG) combined with mometasone furoate nasal spray (MFNS) on the symptoms of children with allergic rhinitis (AR).
methodsSeventy-eight children with AR who visited the Pediatric Department of our hospital from May 2019 to May 2020 were selected and randomly divided into the BTG group (treated with BTG alone), MFNS group (treated with MFNS alone), and combined group (children with the combined use of BTG and MFNS), with 26 cases in each group. The nasal symptoms and oculonasal symptoms were evaluated and observed at baseline and 2 months after treatment.
resultsChildren in the combination group had significantly lower total nasal symptom score (TNSS), total non-nasal symptom score (TNNSS) scores, and visual analogue scale (VAS) scores than those with BTG alone and MFNS alone (
conclusionBTG combined with MFNS can improve the symptoms of sneezing and nasal congestion, which is better than single drug treatment.
Indexed as
Identifiers
35958511PMC9360867W4291674334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.